Key Takeaways
- Drought-hit quarter, margins compressed: Q2 revenue fell 2% YoY to ₹907 crores as the weakest monsoon in over a decade crushed volumes, while high-cost inventory flowing through cost of sales pulled EBITDA margin down 297 bps to 20.5%.
- Domestic business held ground, exports stumbled: Domestic revenue grew 2% on stable selling prices and branded product strength, but exports dropped 23% as shipments to the parent company in Japan halved due to inventory destocking.
- Specialty products are the bright spot: A basket of key specialty brands grew ~22% in value over H1 despite the drought, and India became the first country globally to commercially launch the biostimulant Topgrain.
- H2 outlook stays cautious: Management flagged El Nino strengthening through February, reservoir levels 25% lower than last year, and a delayed Northeast monsoon as headwinds, though firmer crop prices offer some farmer income support.
- What to watch next quarter: Whether the promised inventory normalization actually materializes, the pace of export recovery to Japan, and any concrete announcement on the semiconductor chemicals opportunity for the listed entity.
The Monsoon Shock: What Hit Q2
- A once-in-a-decade drought: The Southwest monsoon arrived late, with June rainfall ~35% below normal and August ~16% below normal, ending the season with a ~13% deficit. IMD declared it officially a drought year, and 16 of 23 key agricultural states recorded more than 10% deficit rainfall.
- Consumption collapsed at the farm gate: Delayed sowing and dry spells reduced herbicide consumption, while farmers skipped spray rounds in August and September, lowering demand for insecticides and fungicides. Production of key crops (rice, cotton, soybean, groundnut, pulses, oilseeds) is estimated lower by almost 10%.
- Volumes fell high single-digits: Q2 sales volumes declined by a high single-digit percentage because of lower consumption in adverse weather conditions.
- The inventory cost trap: Between March and May, input costs rose on Middle Eastern war disruptions, technical price increases, rupee depreciation, and higher packaging, solvent and freight costs. Companies including SCIL passed on increases. From June, prices started falling as monsoon weakness became apparent, leaving the industry carrying high-cost inventory into a period of lower volume and softer prices.
- Margins took the hit: Q2 gross margin fell 240 bps YoY to 40.7% and EBITDA margin fell 297 bps to 20.5% because inventory bought at higher cost between April and June flowed into cost of sales in Q2. In Q1, the company had benefited from lower-cost opening inventory.
- Revenue held broadly stable: H1 revenue was broadly in line with last year despite the clear fall in industry volumes and demand because Q1 revenues were supported by price increases taken between March and June 2026, and Q2 selling prices were kept largely stable.
Suresh Ramachandran: "H1 FY '27 was one of the most difficult first halves for the Indian agrochemical industry in over a decade. The main reason was the erratic and unpredictable monsoon."
Domestic Resilience, Export Stumble
- Domestic business held its ground: Q2 domestic revenues grew 2% to ₹774 crores, with H1 domestic revenue broadly stable at ₹1,657 crores. Branded products made up ~79% of domestic revenue.
- Exports fell sharply on parent-company destocking: Q2 exports declined 23% to ₹127 crores mainly because of timing of shipments to Japan and South America. Exports to Japan almost halved in H1 versus the previous H1 because of inventory buildup at the parent company that is now being liquidated.
- Third-party exports actually grew: Direct third-party exports increased in H1, driven primarily by Africa, and to some extent Brazil and Europe. H1 exports overall were stable at ₹300 crores, with Africa, South America, Asia and Europe each growing 15–19%.
- Branded export share jumped: The share of branded products in exports grew to 41% in H1 from 34% last year, a real increase driven largely by Africa rather than a decline in other segments.
- Japan recovery expected, but not in H2: Management expects the overstocking and inventory liquidation in parent company molecules across the globe to recover in coming months and quarters, but H2 is also expected to be on the softer side this year. From next year, certain capex coming in may bring additional revenues.
Specialty Products: The Growth Engine
- Specialty brands outperformed the drought: Key brands (Flumioxazin/SumiMax, Meshi, Excalia Max, Portion, ProGibb, Nature Dip, TriBasic Copper) all grew in both volume and value, together growing ~22% in value over H1 last year despite the weak monsoon.
- EXCALIA MAX surged: The product grew almost 50% in H1 FY27 in India despite the challenging season, and initial feedback from farmers in the U.S. and Brazil has been very positive. Manufacturing in Tarapur to meet India requirements is expected by the end of this financial year.
- Topgrain: first in the world: India became the first country globally to commercially launch Topgrain, a patented grain-filling biostimulant technology developed by Sumitomo BioRational Company. It was introduced to a limited number of farmers this season, with yield benefit being measured at harvest. A full-fledged launch across the country is planned for next year, with wheat application in the February–March timeframe.
- Helibex launched: A new insecticide to control a key caterpillar pest was launched to a limited extent starting August.
- India now a top-tier launch market: India has been upgraded to the same tier as Brazil, North America, Europe and Japan for early-stage testing of pipeline products from the parent company. Trials are underway for many products, and management expects to introduce 1 or 2 new specialty molecules every year over the next 3 to 5 years.
Suresh Ramachandran: "In the entire world, we are proud to announce that India is the first country to commercially launch this product anywhere in the world."
Category & Product Mix: Where the Pain Was
| Category | Trend | Commentary |
|---|---|---|
| Insecticides (38% of H1 revenue) | ▼ Declined 9% in Q2 | Most affected by weather; farmers skipped spray rounds. |
| Herbicides (25% of H1 revenue) | ▼ Declined 6% in Q2 | Delayed sowing and dry spells reduced consumption. |
| Fungicides | ▼ Declined 6% in Q2 | Lower demand as farmers skipped spray rounds in dry conditions. |
| Metal Phosphides | ▲ Grew 13% in Q2 | Strong performance bucking the broader trend. |
| Animal Nutrition & Environmental Health | ▲ Grew 18% in Q2 | Together grew 18% in Q2; a bright spot outside crop protection. |
| PGRs | ▲ Grew 9% in Q2 | Held broadly flat. |
- Specialty vs generic mix shifted slightly: Specialty fell to 28% from 30% of revenue, while generic rose to 72% from 70% because generic products witnessed higher prices in line with the market.
- Biorational business challenged again: Last year was a complete washout due to rain; this year has been more challenging because of droughts since the Barrix acquisition.
Margins, Costs & Working Capital
- The margin walk: Q2 gross margin fell 240 bps YoY to 40.7% as higher-cost inventory flowed through, though it improved 149 bps QoQ from Q1. EBITDA margin fell 297 bps YoY to 20.5%. Employee expenses (₹70 crores) and other operating expenses (₹113 crores) were both largely flat YoY and well controlled.
- H1 margin objective met: H1 EBITDA margin of 21.3% was broadly in line with historical levels and the stated objective to maintain EBITDA margins equal to or more than 20%.
- Inventory cost normalization underway: Inventory cost levels had largely normalized by the end of Q2 as cost and selling prices came back in line. Management expects inventory to come down to normalized levels through the second half, with corrective actions already started.
- Working capital stretched: Net working capital increased to 76 days from 55 days YoY mainly because inventory days increased from 95 to 115 days, driven by higher inventory cost (prices increased) and softer liquidation and sales in Q2 leaving inventory volumes higher.
- Cash generation held up: Net cash from operations in H1 FY27 was ₹447 crores versus ₹435 crores in H1 FY26. Collections were ₹2,231 crores versus ₹2,277 crores last year, described as reasonable in a difficult collection environment.
- H2 margin outlook stable: Management expects H2 margins to be in the normal range as per historical levels, with no negative raw material cost delta at this point and no adverse situation expected from escalated costs unless the situation changes further.
Kunal Mittal: "...to maintain our EBITDA margins equal to or more than 20% level; which was one of our objective, which we have implemented over last few years."
Capex, Pipeline & the Semiconductor Question
- Dahej greenfield on track: The company is investing ~₹150 crores for a greenfield site at Dahej, with most projects for the parent company's future molecules. Commercial production is expected to start in Q2 FY28. The site is envisioned for development over the next 5 to 10 years.
- Dahej herbicide intermediate: A specific herbicide intermediate project is expected to be commercialized in Q2 FY 2028–29 (calendar 2028, July–October), and may be preponed by a few weeks.
- Tarapur expansion: Two projects of ₹10 crores each (total ₹20 crores) are under implementation to add 3–4 additional products, focused on expanding the domestic business rather than exports. The first part is expected to be completed within the current financial year, and the second part by the end of FY28.
- Additional capex under evaluation: Management is evaluating a few more additional capex projects for the parent company's global needs and will update when approved. Technical studies have been done, and management feels technically confident several projects can be implemented.
- Semiconductor chemicals: early days for the listed entity: The parent company Sumitomo Chemical Japan signed an MOU with a leading semiconductor player in India developing the first fabrication plant during SEMICON 2026. Sumitomo Chemical India is part of some strategic discussions, but nothing concrete, firm, or structured has been defined yet. The first fabrication plant is expected to become operational in the next 1 or 2 years, but products are not candidates to start immediately, and a localization plant will take some time. A new announcement is expected in the next few months.
- Cash deployment: no timeline: Management believes growth opportunities exist in India to deploy cash and does not believe cash should be returned to shareholders at this point. No definitive timeline was given, with deployment dependent on finding a suitable opportunity that fits the strategic scheme.
Kunal Mittal: "Intentions have already made by the both sides, I think made in public also and the MOU was also been signed during SEMICON 2026. However, before a formal communication to the investors and our shareholders and also our stakeholders, I think some more firm level of maturity of the discussions is required."
Good to Great & Management Transition
- New leadership in place: Dr. Suresh Ramachandran took charge as Managing Director on 1st September 2026, succeeding Mr. Chetan Shah, who was appointed as Non-Executive Non-Independent Director and Chairman of the Board. Mr. Sushil Marfatia completed his term as Executive Director, and Mr. Anand Mohan Tiwari joined the Board as an Independent Director.
- Good to Great transformation launched: A company-wide program built on five pillars (people, operational excellence, technology, data/digital/automation, and cross-functional success) was launched from 1st September 2026. All key leaders have identified initiatives across the five buckets, data is being collated, and a financial goal is expected in the next few weeks.
- Innovation turnover index targeted at 9–10%: Management is targeting 9% to 10% of revenue from new products every year.
Suresh Ramachandran: "Our commitment to you is continuity. The strategy, the financial discipline and the farmer-first approach that delivered our results over the last several years remain unchanged. What we are adding is a sharper focus on execution, which we call our Good to Great initiative..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin floor | Maintain EBITDA margins equal to or more than 20% | Ongoing |
| Inventory normalization | Bring inventory down to normalized levels through H2 | H2 FY27 |
| Dahej commercial production | Commercial production to start | Q2 FY28 |
| Tarapur expansion (part 1) | First part of ₹20 crore capex to add 3–4 products | Within FY27 |
| Tarapur expansion (part 2) | Second part completion | By end of FY28 |
| INDIFLIN (EXCALIA MAX) manufacturing | Manufacturing in Tarapur to meet India requirement | By end of FY27 |
| Dahej herbicide intermediate | Commercialization of specific intermediate project | Q2 FY 2028–29, possibly preponed |
| New product introductions | 1 or 2 new specialty molecules every year | Over next 3 to 5 years |
| Innovation turnover index | 9% to 10% of revenue from new products | Every year |
| Semiconductor announcement | More conclusive understanding and formal announcement | Next few months |
| Good to Great financial goal | Financial objective and goal to be set | Next few weeks |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹907 cr, down 2% YoY |
| H1 FY27 revenue | ₹1,971 cr, down 1% YoY |
| Gross margin | 40.7%, down 240 bps YoY; improved 149 bps QoQ |
| EBITDA margin | 20.5%, down 297 bps YoY |
| H1 FY27 EBITDA margin | 21.3% vs 22% last year |
| Net profit | ₹157 cr, down 11% YoY |
| Net profit margin | 17.3% |
| H1 FY27 net profit | ₹372 cr, up 5% YoY; net profit margin 18.9%, improved 96 bps |
| H1 FY27 EPS | ₹7.45 vs ₹7.13 last year |
| Domestic revenue | ₹774 cr, grew 2% YoY |
| Exports revenue | ₹127 cr, declined 23% YoY |
| H1 branded products share of export revenue | 41%, up from 34% last year |
| H1 specialty products share of revenue | 28% vs 30% last year |
| Cash and liquid investments | ~₹2,523 cr as of 30 Sep 2026, up from ₹2,113 cr in Mar 2026 |
| Net cash from operations (H1 FY27) | ₹447 cr vs ₹435 cr in H1 FY26 |
| Net working capital days | 76 days as of Sep 2026 vs 55 days in Sep 2025 |
| Inventory days | 115 days as of Sep 2026 vs 95 days in Sep 2025 |
| Innovation turnover index | High single digit, 9% to 10% every year-on-year |